From PerfusionWiki
Revision as of 13:57, 11 June 2021 by (talk) (→‎References)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Trade Name

Cordarone, Parcerone


Class III Antiarrhythmic Drug

ECC Consideration

Metabolized and excreted via the liver, note decreased excretion in patients with liver deficiencies and during hypothermia.


Adults: ECC Doses

  • Loading Dose: First 150mg over the first 10min (15mg/min)
  • Following Dose: 360mg over the next 6 hours (1mg/min)
  • Maintenance: 540 mg over the remaining 18 hours (.5mg/min)

Ventricular Arrhythmias

  • IV: 15 mg/min for 10 min, then 1 mg/min for 6 hours, then maintain 0.5 mg/min continuous infusion.
  • Supraventricular Arrhythmias: IV: 300 mg IV over 1 hour

Decrease in severe liver deficiency


Recurrent ventricular fibrillation or hemodynamically unstable ventricular tachycardia, supraventricular arrhythmias, atrial fibrillation

Adverse Effects

Alcoholism, arrhythmia exacerbation, AV block, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, requires an experienced clinician, sick sinus syndrome


Sinus node dysfunction, 2nd or 3rd degree AV block, sinus bradycardia (without pacemaker), Iodine hypersensitivity, Cardiogenic shock, heart failure, hypotension, hypovolemia, ventricular dysfunction